Anticoagulation in Stroke.

Slides:



Advertisements
Similar presentations
Prosthetic Valve; Anticoagulation After ICH Dr.Tahsin.N.
Advertisements

JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.
TPA… SMART or not SMART? That is the Question. Sarah Parker, MD.
Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.
Apixaban versus Aspirin in Atrial Fibrillation Patients ≥ 75 years old: An Analysis from the AVERROES Trial Kuan H Ng, Olga O Shestakovska, John W. Eikelboom,
STROKESTROKESTROKESTROKE. Why Change? Improve Mortality Improve Mortality Devastating and Life Altering Devastating and Life Altering Cost expense of.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
Richard Leigh, M.D. Johns Hopkins University School of Medicine.
CLINICAL CASES.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
Jonathan A. Edlow, MD, FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral.
Transient Ischemic Attack (TIA): The Calm Before the Storm
Atrial Fibrillation Warfarin and its newer alternatives
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
Secondary prevention after a TIA or ischemic stroke.
Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency Heyder Omran, Giso von der Recke,
Anticoagulation Transitions: Perioperative Care Alan Brush, MD, FACP Clinical Co-Director, Anticoagulation Management Service Harvard Vanguard Medical.
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
Jim Hoehns, Pharm.D.. Lancet 2013;382: Albers G et al. Chest. 2001; 119 (suppl): 300S. Ischemic stroke 85% Hemorrhagic stroke 15% Other 5% Cryptogenic.
UBC-Case 1 Samuel Yip PhD, MD, FRCPC Western Stroke Day 2012.
Update in ESC: Dabigatran among OAC
Clinical Overview Director, Stanford Stroke Center Stanford University Palo Alto, California Gregory W. Albers, MD.
Long-Term Comparison of Medical Treatment With Percutaneous Closure of Patent Foramen Ovale for Secondary Prevention of Paradoxical Embolism: A Propensity-Score.
Rikki Weems, PGY III August 20, 2015
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Cardioembolic Stroke: Diagnosis and Management
Disclosure Statement of Financial Interest
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural.
R4 문정락 / IC prof. 김진배 Lancet Haematol 2015;2: e150–59.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
ESUS in the Athens Stroke Registry George Ntaios University of Thessaly, Larissa/Greece Barcelona, 08 June 2016.
Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.
Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.
IN THE NAME OF GOD Dr. h-kayalha Anesthesiologist.
CARDIOEMBOLIC STROKE Debasis Das, MD, FACC Interventional Cardiologist CHI St. Vincent Heart Clinic Arkansas April 25, 2015.
© free-ppt-templates.com 2017 AHA/ACC Focused Update of Valvular Heart Disease Guideline of 2014 DR. OMAR SHAHID TR CARDIOLOGY SZH.
Cryptogenic Stroke and AF
The patient with atrial fibrillation who needs PCI
Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.
Management of Patients on Chronic Oral Anticoagulant Therapy
Table 1: Table 2: Non Therapeutic Angiograms in Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Does not Adversely Affect Patient.
Difficult situations in anticoagulation after stroke
The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,
Acute Stroke Therapy with IV Thrombolysis Lawrence R. Wechsler, M.D.
When should aspirin be dropped from triple therapy?
You can never be too Thin…. An Update on NOACs
How Do We Incorporate Patient Perspectives Into Clinical Trial Design?
Is There a Need to Address AF in patients Undergoing Valve Surgery?
David R. Holmes, Jr., M.D. Mayo Clinic, Rochester
A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes
Cardiovascular Research Technology Conference (CRT 17)
Anticoagulation in Atrial Fibrillation
Antithrombotic Therapy
Novel oral anticoagulants in comparison with warfarin
Click here for title Click here for subtitle
Setareh Omran, MD Vascular Neurology Fellow
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Approach to Hemorrhagic and Ischemic Strokes
Strokes.
Etiology of stroke Sanjeeva Onteddu.
Selecting NOACs for High-Risk Patients
Bridging Anticoagulation
Which NOAC and When for Stroke Prevention in AF?
Extended Window Thrombectomy
(p for noninferiority = 0.01)
Update from education committee
What Happens When your patient is transferred .
Presentation transcript:

Anticoagulation in Stroke. Sanjeeva Reddy Onteddu. Vascular Neurology.

Disclosures. Have a 3 year old. We both worked on it. No financial relations.

Objectives.

Objectives. Who should be anticoagulated When should be anticoagulated What should be used to Anticoagulate. Ultimate goal …. Will be revealed at the end

Ischemic Stroke

Who

All ischemic stroke patients. 20-30 years ago MGH: Acute stroke AC vs Antiplatelet study.

Easy ones first Need Neurology clearance Has LV thrombus, No neurological deficits: yes Has A fib, no neurological deficits:

Other thrombotic states DVT/PE Known hypercoagulable states.

Cardiac Causes PFO- No PFO with large ASA – may be, no large trials, case series and reports. LV thrombus – Yes but when Mechanical Valve – Yes and how soonish.

A fib

What about Bleeding risk

CHA2DS2-VASc Vs HAS-BLED Other Bleeding Scores ATRIA HEMORR2HAGES Use these to Identify factors which increase risk of bleeding and treat them.

Other etiologies of ischemic Stroke Lacunar – No Stuttering Lacunar – give it a try. Carotid Atherosclerosis – no Carotid Dissection – May be Cryptogenic Strokes: Not yet

Cryptogenic strokes WARSS: No difference in cryptogenic pts with Coumadin vs ASA. RESPECT-ESUS Study: We are Enrolling please send patients. Second Cryptogenic strokes: Discuss with patients I usually do. CLINICAL PRACTICE. Cryptogenic Stroke. Saver JL, N Engl J Med. 2016 May;374(21):2065-74.  Some papers suggest Use CHA2DS2-VASc score even if A fib not detected.

Cervical Dissections. Intracranial Dissection: No Acute thrombus identified Recurrent Ischemic symptoms multiple dissections (15.2%) Intracranial Dissection: No

Cerebral Venous Thrombosis Without ICH: Yes With ICH: Yesissh

Meta anyalsis: Recurrent CVT higher in patient who were taking Coumadin, no benefit. No Large Randomized controlled trials, Few studies non statistical significance. Few Question the need for AC. Expert Opinion/Guidelines 2011 AHA/ASA is to AC.

Complex patients

ICH patients Wait….. What…… Not All Only who are high risk of Thromboembolic events. Patients with A fib, Hypercoag states Etc.

Hemorrhagic Stroke Any Intracranial hemorrhage – Not acutely ICH with A fib – May be things to consider Etiology of ICH- Hypertensive vs others, using AC at the time of incident ICH Supra therapeutic/not supra therapeutic with Coumadin Using NOAC’s

More risk of Recurrence if ICH Recurrence More risk of Recurrence if Uncontrolled hypertension Lobar location of initial ICH Ongoing anticoagulation Greater number of micro bleeds on MRI Recurrence of ICH after resumption of anticoagulation with VK antagonists, CHIRONE Study. 7.5% Recurrent Risk with median ICH recurrence time 16.5 months.

Mechanical Valves and ICH ICH with Mechanical Valve: Yes When Safety vs Stroke

Mechanical Valves Frequency of thromboembolic events: 0.7 to 1 percent per patient per year with Coumadin. 2.2 percent per patient per year with ASA  4 percent with no anticoagulation. Mitral valve prostheses twice the risk compared with those aortic valve prostheses. valve thrombosis is 1.8% a year Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89(2):635. 

Cerebral Amyloid Angiopathy. Can we AC patients with CAA: NO With Coumadin 7-10 fold increased risk. What about tPA: no information might be bliss … If more than 5 micro hemorrhages risk of Symptomatic ICH is high, should discuss with family. Antiplatelet: Risk Vs benefit.

Stroke clearance for cardiac surgeries Aortic dissection Risk Vs Benefit. Things to consider Size of stroke Need for surgery Time since stroke Presence of ICH/Petichial hemorrhage

Endocarditis with Septic Embolic/Mycotic Aneurysms. Need Vessel imaging if mycotic aneurysm suspected. tPA with possible septic Emboli: Contraindication

Afib + Falls ? AC Need to fall 295 times a year for fall-related subdural hemorrhages to outweigh benefits of stroke prevention. Choosing Antithrombotic Therapy for Elderly Patients With Atrial Fibrillation Who Are at Risk for Falls, Arch Intern Med. 1999;159(7):677-685. doi:10.1001/archinte.159.7.677

When to start it.

A fib and stroke Treatment started with in 48hrs of stroke more bleeds Non significant decreased ischemic strokes Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials.AUPaciaroni M, Stroke. 2007;38(2):423.

A fib stroke timing Factors affecting decisions High CHA2DS2-VASc score High National Institutes of Health Stroke Scale, Large ischemic lesions Type of anticoagulant administered each independently led to a greater risk of recurrence and bleedings. Best time to start AC is 4 to 14 days from stroke onset. Patients treated with oral anticoagulants alone had better outcomes compared with patients treated with low molecular weight heparins alone or before oral anticoagulants.

Proposed AC timelines

Other Indications needing AC Similar decision making process Size of stroke, presence of micro hemorrhages, co morbid conditions etc. Large infarcts > one-third of the middle cerebral artery territory More than one-half of the posterior cerebral artery NIHSS or Clinical Exam will give a clue

ICH patients needing AC Still Not Sure if we need to do it?

Swedish Stroke Registry No etiology for ICH 2619 ICH Survivors the net benefit for all events was not statistically significant before 7 weeks. Conclusion 7-8 Weeks is safe

How Long to Wait for MHV and ICH Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk.Phan TG, Koh M, Wijdicks EF, Arch Neurol. 2000 Dec; 57(12):1710-3. The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves.Wijdicks EF, Schievink WI, Brown RD, Mullany CJNeurosurgery. 1998 Apr; 42(4):769-73. 1-2 week Discontinuation is safe Management of intracranial bleeding associated with anticoagulation: balancing the risk of further bleeding against thromboembolism from prosthetic heart valves.Crawley F, Bevan D, Wren D J Neurol Neurosurg Psychiatry. 2000 Sep; 69(3):396-8. No need for bridging? Restarting anticoagulation in prosthetic heart valve patients after intracranial haemorrhage: a 2-year follow-up.Butler AC, Tait RC Br J Haematol. 1998 Dec; 103(4):1064-6. Hold for 7 days no TE’s Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. A systematic review.Romualdi E, Micieli E, Ageno W, Squizzato A, Thromb Haemost. 2009 Feb; 101(2):290-7. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion.Aguilar MI, Hart RG, Kase CS, Freeman WD, Hoeben BJ, García RC, Ansell JE, Mayer SA, Norrving B, Rosand J, Steiner T, Wijdicks EF, Yamaguchi T, Yasaka M Mayo Clin Proc. 2007 Jan; 82(1):82-92. Review of recent studies found Low risk of TE and safe to hold for 7-14 days.

What to Use Bridge vs No Bridge Warfarin vs NOAC Which NOAC Money matters

Bridge Vs no Bridge Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation, N Engl J Med 2015; 373:823-833August 27, 2015DOI: 10.1056/NEJMoa1501035. No benefit

For Stroke patients?? Anticoagulation After Cardioembolic Stroke: To Bridge or Not to Bridge? Arch Neurol. 2008 Sep; 65(9): 1169–1173.

Who Needs Bridging To consider High Risk of Thrombo embolic events Low risk of Hemorrhagic conversion or Hematoma Expansion. Good Blood pressure Control To avoid Large ICH High risk of bleeding, low platelets… Renal failure…

Who Needs Bridging Patients with LV thrombus. Mechanical Valves? Carotid Dissection with fresh thrombus, multiple recurrent strokes. CVT: Sure

Heparin for acute stroke patients, you decided to bridge. No Boluses

Coumadin is Warfarin BLEEDING OCCURS IN 2% TO 3% OF PATIENTS PER YEAR.

Still Coumadin LV thrombus APL Cerebral venous Thrombosis Mainly because they have not been studied Mechanical Valve: Pradaxa worse than Coumadin, RE-ALIGN trial Others NOAC’s not studied.

For A fib Coumadin vs NOAC’s All compared to Coumadin No head – head comparisons. Different rates of therapeutic INR’s Recommendations now changing to NOAC’s as first line.

Apixaban: Less side effects. Reversal Agents ?? Dabigatran Has Praxbind So some might be comfortable.

Questions

Anticoagulation and stroke.   Anticoagulants versus antiplatelet agents for acute ischaemic stroke.Berge E, Sandercock P 2014 Anticoagulants for acute ischaemic stroke. Sandercock PA, 2015. CAA and Anticoagulation Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Rosand J, Neurology. 2000;55(7):947. How to AC Validation of a weight-based nomogram for the use of intravenous heparin in transient ischemic attack or stroke.AUToth C, . 2002;33(3):670.  PFO References Lamy C, Giannesini C, Zuber M, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. Stroke 2002; 33:706. Serena J, Marti-Fàbregas J, Santamarina E, et al. Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke 2008; 39:3131. Homma S, Sacco RL, Di Tullio MR, et al. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002; 105:2625. Dissection Reference Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial The CADISS trial investigators* Characteristics and Outcomes of Patients With Multiple Cervical Artery Dissection Yannick Béjot, MD, PhD on behalf of the CADISP Group